Cardiovascular Health in Menopause Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Cardiovascular Health in Menopause. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Cardiovascular Health in Menopause Indian Medical PG Question 1: Which among the following is an absolute contraindication of Hormone replacement therapy?
- A. Endometriosis
- B. Heart disease
- C. Breast carcinoma (Correct Answer)
- D. Osteoarthritis
Cardiovascular Health in Menopause Explanation: ### Breast carcinoma
- Hormone replacement therapy (HRT) is **contraindicated** in breast carcinoma because many breast cancers are **estrogen-receptor positive**, meaning estrogen can stimulate their growth [1].
- Using HRT in patients with a history of breast cancer significantly increases the risk of **recurrence** or **progression** of the disease [1].
*Endometriosis*
- Endometriosis is not an **absolute contraindication**; HRT can sometimes be used in women with a history of endometriosis, especially if a hysterectomy and bilateral oophorectomy have been performed.
- However, unopposed estrogen therapy might **exacerbate** remaining endometrial implants, so a combined estrogen-progestin regimen is typically preferred [1].
*Heart disease*
- While HRT has been shown to have **risks** in women with established coronary heart disease, it is not an absolute contraindication for all forms of heart disease.
- The **Women's Health Initiative study** demonstrated increased cardiovascular events in older women initiating HRT, but current guidelines suggest that timing of initiation is crucial and benefits may outweigh risks for younger postmenopausal women.
*Osteoarthritis*
- Osteoarthritis is **not a contraindication** to HRT; in fact, some studies suggest that estrogen may have protective effects on cartilage [2].
- HRT is neither a treatment nor a contraindication for osteoarthritis and does not significantly impact its progression or severity [2].
Cardiovascular Health in Menopause Indian Medical PG Question 2: The non-modifiable risk factor for hypertension is -
- A. Environment stress
- B. Obesity
- C. Salt intake
- D. Age (Correct Answer)
Cardiovascular Health in Menopause Explanation: ***Age***
- Age is a **non-modifiable** risk factor because it is an inherent biological process that cannot be changed. [3]
- The risk of developing **hypertension** generally increases with advancing age due to arterial stiffening and other physiological changes. [1]
*Environment stress*
- **Environmental stress** is considered a **modifiable** risk factor because individuals can learn coping mechanisms or make lifestyle changes to reduce its impact.
- Chronic stress can lead to **sympathetic nervous system activation**, contributing to elevated blood pressure. [4]
*Obesity*
- **Obesity** is a **modifiable** risk factor, as it can be directly addressed through diet, exercise, and other lifestyle interventions. [2]
- It increases the risk of hypertension by fostering **insulin resistance**, **inflammation**, and increased **cardiac output**.
*Salt intake*
- **Salt intake** is a **modifiable** risk factor as it can be controlled through dietary choices. [2]
- Excessive sodium consumption can lead to **fluid retention** and increased blood volume, thereby raising blood pressure.
Cardiovascular Health in Menopause Indian Medical PG Question 3: Estrogen administration in a menopausal woman increases the:
- A. Bone mass (Correct Answer)
- B. Gonadotropin secretion
- C. Muscle mass
- D. LDL cholesterol
Cardiovascular Health in Menopause Explanation: ***Bone mass***
- Estrogen plays a crucial role in maintaining **bone density** by inhibiting osteoclast activity and promoting osteoblast function.
- In menopausal women, estrogen administration counteracts bone loss and thus **increases bone mass**, reducing the risk of osteoporosis.
*Gonadotropin secretion*
- In menopausal women, **gonadotropin-releasing hormone (GnRH)** and subsequent **FSH and LH levels are elevated** due to the absence of ovarian estrogen feedback.
- Estrogen administration would exert a **negative feedback** on the hypothalamus and pituitary, thereby **decreasing**, not increasing, gonadotropin secretion.
*Muscle mass*
- While estrogen has some anabolic effects, **androgens** (like testosterone) are the primary hormones responsible for significantly increasing muscle mass.
- Estrogen administration to menopausal women is not a primary intervention for increasing muscle mass; its effects on this parameter are generally **modest or negligible**.
*LDL cholesterol*
- Estrogen generally has a **favorable effect on lipid profiles**, typically leading to a **decrease in LDL cholesterol** and an increase in HDL cholesterol.
- Therefore, estrogen administration would generally **reduce**, not increase, LDL cholesterol levels.
Cardiovascular Health in Menopause Indian Medical PG Question 4: What is the effect of progesterone on lipids?
- A. Lowers HDL and lowers LDL
- B. Lowers HDL and increases LDL (Correct Answer)
- C. Lowers LDL, increases HDL
- D. Increases LDL and HDL
Cardiovascular Health in Menopause Explanation: ***Lowers HDL and increases LDL***
- This describes the effect of **synthetic progestins** (particularly older generation ones like levonorgestrel) on lipid profiles.
- Synthetic progestins have been shown to **decrease HDL cholesterol** and **increase LDL cholesterol**, contributing to an unfavorable cardiovascular risk profile.
- **Natural progesterone** has minimal or neutral effects on lipids, but this question refers to the progestin effects commonly discussed in contraceptive and hormone replacement therapy contexts.
- This is the **classical teaching** for progesterone effects on lipids in most medical textbooks.
*Lowers LDL, increases HDL*
- This effect is characteristic of **estrogen**, not progesterone.
- Estrogen improves lipid profiles by increasing HDL and lowering LDL cholesterol.
- Progestins generally have opposite or antagonistic effects compared to estrogen on lipid metabolism.
*Lowers HDL and lowers LDL*
- While synthetic progestins do lower HDL, they typically **increase LDL**, not lower it.
- A simultaneous decrease in both HDL and LDL is not a characteristic effect of progesterone or progestins.
*Increases LDL and HDL*
- Synthetic progestins tend to increase LDL, but they typically **lower HDL**, not increase it.
- An increase in both LDL and HDL simultaneously is not a typical effect of progesterone on lipid metabolism.
Cardiovascular Health in Menopause Indian Medical PG Question 5: Hormone Replacement Therapy (HRT) in postmenopausal women is beneficial in all these except
- A. Vaginal atrophy
- B. Osteoporosis
- C. Vasomotor symptoms
- D. Prevention of CAD (Correct Answer)
Cardiovascular Health in Menopause Explanation: ***Prevention of CAD***
- While HRT was initially thought to be cardioprotective, large-scale studies like the **Women's Health Initiative (WHI)** demonstrated that it does **not prevent coronary artery disease (CAD)** and may even increase the risk of cardiovascular events, especially in older postmenopausal women or those initiating therapy years after menopause.
- The potential benefits regarding CAD prevention are outweighed by risks such as **stroke** and **venous thromboembolism**.
*Vaginal atrophy*
- **Estrogen deficiency** in postmenopausal women leads to thinning, dryness, and inflammation of the vaginal walls, causing symptoms like dryness, irritation, and painful intercourse.
- **Local or systemic estrogen therapy** effectively reverses these changes by restoring vaginal tissue health.
*Osteoporosis*
- **Bone loss** accelerates after menopause due to declining estrogen levels, increasing the risk of osteoporosis and fractures.
- HRT, particularly estrogen, is effective in **preventing and treating osteoporosis** by inhibiting bone resorption and preserving bone mineral density.
*Vasomotor symptoms*
- **Hot flashes** and **night sweats** are common and often debilitating symptoms of menopause, directly linked to fluctuating and declining estrogen levels.
- HRT, especially systemic estrogen, is the **most effective treatment** for alleviating these symptoms by stabilizing thermoregulatory control.
Cardiovascular Health in Menopause Indian Medical PG Question 6: Which of the following is a beneficial effect of hormone replacement therapy in early menopause?
- A. Increased Endothelin
- B. Increased TNF-α
- C. Increased Nitric oxide (Correct Answer)
- D. Decreased COX-2
Cardiovascular Health in Menopause Explanation: ***Increased Nitric oxide***
- **Estrogen** in HRT increases the production and bioavailability of **nitric oxide (NO)** by upregulating endothelial nitric oxide synthase (eNOS).
- Increased NO leads to **vasodilation**, contributing to cardiovascular benefits and improved endothelial function.
*Increased Endothelin*
- **Endothelin-1** is a potent vasoconstrictor, and increased levels are generally associated with **endothelial dysfunction** and cardiovascular risk.
- HRT, particularly estrogen, tends to decrease endothelin-1 levels or counteract its effects, leading to beneficial vascular responses.
*Increased TNF-α*
- **Tumor Necrosis Factor-alpha (TNF-α)** is a pro-inflammatory cytokine, and elevated levels are linked to chronic inflammation and increased risk of various diseases.
- HRT, especially estrogen, typically has **anti-inflammatory effects**, potentially reducing TNF-α levels or mitigating its inflammatory actions.
*Decreased COX-2*
- **Cyclooxygenase-2 (COX-2)** is an enzyme involved in inflammation and pain pathways; its decrease is generally anti-inflammatory.
- However, the primary beneficial vascular effect of HRT is not through direct inhibition of COX-2 but rather through mechanisms like increasing nitric oxide.
Cardiovascular Health in Menopause Indian Medical PG Question 7: Senile vaginitis is due to :
- A. Diabetes
- B. Gonococcal infection
- C. Oestrogen deficiency (Correct Answer)
- D. Cancer cervix
Cardiovascular Health in Menopause Explanation: ***Oestrogen deficiency***
- **Senile vaginitis**, also known as **atrophic vaginitis**, is primarily caused by **decreased oestrogen levels**, particularly after menopause.
- Reduced oestrogen leads to thinning and drying of the vaginal walls, making them more susceptible to inflammation and infection.
*Diabetes*
- While uncontrolled **diabetes** can increase the risk of vaginal infections, such as **candidiasis**, it is not the direct cause of senile vaginitis itself.
- Diabetic neuropathy can affect vaginal sensation, but does not cause the atrophic changes observed in senile vaginitis.
*Gonococcal infection*
- **Gonococcal infection** is a sexually transmitted infection that causes acute inflammation of the mucous membranes, but not the long-term atrophic changes seen in senile vaginitis.
- It would present with purulent discharge and dysuria, which are distinct from the symptoms of senile vaginitis.
*Cancer cervix*
- **Cervical cancer** is a malignancy of the cervix and does not directly cause senile vaginitis.
- While it can manifest with abnormal vaginal bleeding or discharge, these symptoms are typically due to the tumor itself and not the atrophic changes characteristic of senile vaginitis.
Cardiovascular Health in Menopause Indian Medical PG Question 8: What is the primary hormonal cause of hot flushes experienced during menopause?
- A. Increased noradrenaline with normal estrogen levels
- B. Increased noradrenaline
- C. Decreased estrogen levels (Correct Answer)
- D. Both increased noradrenaline and decreased estrogen levels
Cardiovascular Health in Menopause Explanation: ***Decreased estrogen levels***
- **Decreased estrogen** is the primary hormonal change during menopause, leading to thermoregulatory dysfunction in the hypothalamus.
- This hormonal imbalance causes the **vasomotor symptoms** like hot flushes and night sweats.
*Increased noradrenaline*
- While **noradrenaline** (norepinephrine) is involved in thermoregulation, its increase is a **secondary event** triggered by the initial estrogen deficiency, not the primary cause.
- Increased noradrenaline can exacerbate the **vasodilation** and heat dissipation experienced during a hot flush.
*Increased noradrenaline with normal estrogen levels*
- This option is incorrect because hot flushes are characteristic of menopause, which is defined by **decreased estrogen levels**.
- **Normal estrogen levels** would typically prevent the severe thermoregulatory instability that causes hot flushes.
*Both increased noradrenaline and decreased estrogen levels*
- Although both factors are involved, the question asks for the **primary hormonal cause**. **Decreased estrogen** initiates the cascade of events, including the subsequent alteration of neurotransmitter levels like noradrenaline.
- Noradrenaline's role is more of a **mediator** in the physiological response to the primary estrogen deficiency.
Cardiovascular Health in Menopause Indian Medical PG Question 9: In menopause, which of the following is seen:
- A. High FSH (Correct Answer)
- B. High progesterone
- C. High estrogen
- D. Low FSH
Cardiovascular Health in Menopause Explanation: ***High FSH***
- In **menopause**, the ovaries lose their ability to produce **estrogen** and **progesterone**, leading to a decline in their levels.
- This decline in ovarian hormones removes the **negative feedback** on the **hypothalamus** and **anterior pituitary**, causing a compensatory increase in **gonadotropin-releasing hormone (GnRH)**, **follicle-stimulating hormone (FSH)**, and **luteinizing hormone (LH)**.
*High progesterone*
- **Progesterone** levels are typically **low** in menopause because the ovaries are no longer ovulating or producing the corpus luteum, which is the primary source of progesterone.
- While progesterone is important in the normal menstrual cycle, its production ceases after the final menstrual period.
*High estrogen*
- **Estrogen** levels are generally **low** in menopause due to the cessation of ovarian follicular activity.
- The decline in estrogen is responsible for many menopausal symptoms, such as hot flashes and vaginal dryness.
*Low FSH*
- **Low FSH** is typically seen in conditions where there is sufficient **estrogen** and **progesterone** exerting negative feedback on the pituitary, or in primary pituitary/hypothalamic dysfunction.
- In menopause, the **lack of ovarian hormones** specifically causes FSH (and LH) levels to be significantly elevated.
Cardiovascular Health in Menopause Indian Medical PG Question 10: HRT improves -
- A. Dementia
- B. Coronary artery disease
- C. Bone density (Correct Answer)
- D. Endometrial cancer risk
Cardiovascular Health in Menopause Explanation: ***Bone density***
- **Hormone replacement therapy (HRT)** effectively prevents bone loss and reduces the risk of **osteoporosis** and fractures in postmenopausal women.
- **Estrogen** plays a crucial role in maintaining bone density by inhibiting osteoclast activity and promoting osteoblast activity.
*Dementia*
- Studies have shown that HRT does not improve or prevent dementia and may even increase the risk of cognitive decline in older women.
- The timing of HRT initiation relative to menopause may influence its effect on cognitive function, with later initiation potentially being less beneficial or even harmful.
*Coronary artery disease*
- While earlier beliefs suggested HRT might be protective, large clinical trials have demonstrated that HRT does not reduce the risk of **coronary artery disease** and may even increase it in some populations.
- The effects on cardiovascular health are complex and depend on factors such as age, time since menopause, and individual risk factors.
*Endometrial cancer risk*
- **Unopposed estrogen** HRT significantly increases the risk of **endometrial cancer**.
- This risk is mitigated by combining estrogen with **progestin** in women with an intact uterus.
More Cardiovascular Health in Menopause Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
